Plain-English translation of NCT05270525 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new inhaled medication called to see if it can help reduce inflammation in the lungs of people with COPD (a chronic lung disease that makes breathing difficult). You would receive both the medication and a placebo (inactive treatment) at different times during the study, so researchers can compare how each affects inflammation in your sputum (the mucus you cough up). The goal is to understand whether this treatment could help people with COPD breathe better.
COPD causes long-term inflammation and damage to the airways, making it harder to breathe over time. Current treatments help manage symptoms, but doctors are looking for new options that could reduce the underlying inflammation and slow disease progression.
You likely qualify if…
You likely don't qualify if…
Over 22–24 weeks, you would visit the clinic about 7 times and receive phone calls between visits. You would receive the medication (or placebo) by nebulizer twice daily for 8 weeks, then take a 4-week break using only your regular COPD maintenance therapy, and then receive the opposite treatment for another 8 weeks. During the study, you would also produce sputum samples so researchers can measure inflammation, and you would continue using your usual COPD rescue inhaler as needed.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States